Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CYTIP drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CYTIP Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for PPI assays. |
View CYTIP Products |
| Gene Delivery | CYTIP Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression validation. |
View CYTIP Products |
| Benchmark Ab | Anti-CYTIP Recombinant Antibody High-affinity positive control for Western Blot, Immunoprecipitation, and IHC. |
View CYTIP Products |
| Validator | CYTIP siRNA Set For knockdown verification and functional specificity assays. |
View CYTIP Products |
| Related Target A | CYTH2 (Cytohesin-2 / ARNO) Direct binding partner of CYTIP; critical for cytohesin-mediated LFA-1 activation pathways. |
View CYTH2 Products |
| Related Target B | ITGAL (LFA-1 alpha / CD11a) Downstream effector of the CYTIP-cytohesin regulatory axis in leukocyte adhesion. |
View ITGAL Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) screening (CYTIP-CYTH2) | High-purity human recombinant CYTIP and CYTH2 proteins with precise tag configurations (GST/His/Flag) for TR-FRET/AlphaLISA. |
| Intracellular targeting & transfection efficiency | Lentiviral particles engineered for high-titer transduction in primary T cells and suspension cell lines. |
| Lack of Controls | Sequence-verified biosimilar and benchmark antibodies included for assay standardization. |
| False Positives | Validated siRNA pools included to confirm target-specific phenotypic knockdown. |
Live CYTIP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CYTIP therapeutics is intensifying, with major players shifting focus from traditional cell-surface receptors to intracellular scaffolding proteins that modulate immune cell trafficking. As first-generation immunotherapies encounter resistance, the next wave of R&D is targeting CYTIP to decouple integrin activation and overcome the physical barriers of the immunosuppressive tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Biotech Startups, Academic Consortia | Autoimmune Diseases, Solid Tumors | In vitro binding assays (Need high-purity CYTIP & CYTH2 recombinant proteins) |
| PROTAC (Targeted Degradation) | Platform Technology Corporates | Hematological Malignancies | Ubiquitination assays & Western Blot validation (Need sequence-verified antibodies) |
| Gene Therapy / RNAi | RNA Therapeutics Specialists | Chronic Inflammatory Disorders | Knockdown efficiency validation (Need validated siRNA and Lentiviral systems) |